S
Stéphane Pillet
Researcher at McGill University Health Centre
Publications - 18
Citations - 873
Stéphane Pillet is an academic researcher from McGill University Health Centre. The author has contributed to research in topics: Immunogenicity & Vaccination. The author has an hindex of 12, co-authored 18 publications receiving 481 citations. Previous affiliations of Stéphane Pillet include Montreal General Hospital.
Papers
More filters
Journal ArticleDOI
Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19.
Brian J. Ward,Philipe Gobeil,Annie Séguin,Judith Atkins,Iohann Boulay,Pierre-Yves Charbonneau,Manon Couture,Marc-André D'Aoust,Jiwanjeet Dhaliwall,Carolyn Finkle,Karen Hager,Asif Mahmood,Alexander I. Makarkov,Matthew P. Cheng,Stéphane Pillet,Patricia Schimke,Sylvie St-Martin,Sonia Trépanier,Nathalie Landry +18 more
TL;DR: In this paper, the authors report Day 42 interim safety and immunogenicity data from an observer-blinded, dose escalation, randomized controlled study of a virus-like particle vaccine candidate produced in plants that displays the SARS-CoV-2 spike glycoprotein (CoVLP: NCT04450004 ).
Journal ArticleDOI
A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults.
Stéphane Pillet,Éric Aubin,Sonia Trépanier,Diane Bussière,Michèle Dargis,Jean-François Poulin,Bader Yassine-Diab,Brian J. Ward,Nathalie Landry +8 more
TL;DR: Plant-based QVLP offers an attractive alternative manufacturing method for producing effective and HA-strain matching seasonal influenza vaccines and induced a substantial and sustained increase of hemagglutinin-specific polyfunctional CD4 T cells.
Journal ArticleDOI
Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18–64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials
Brian J. Ward,Alexander I. Makarkov,Annie Séguin,Stéphane Pillet,Sonia Trépanier,Jiwanjeet Dhaliwall,Michael Libman,Timo Vesikari,Nathalie Landry +8 more
TL;DR: Two phase 3 efficacy studies of a recombinant quadrivalent virus-like particle (QVLP) influenza vaccine manufactured in plants in adults aged 18-64 years and 65-plus, showing relative vaccine efficacy to prevent laboratory-confirmed influenza-like illness caused by any influenza strain are described.
Journal ArticleDOI
Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate—Two randomized Phase II clinical trials in 18 to 49 and ≥50 years old adults
Stéphane Pillet,Julie Couillard,Sonia Trépanier,Jean-François Poulin,Bader Yassine-Diab,Bruno Guy,Brian J. Ward,Nathalie Landry +7 more
TL;DR: Overall, the 30 μg dose produced the most consistent humoral and cellular responses in both 18–49 and ≥50 years old subjects, strongly supporting the clinical development of this candidate vaccine.
Journal ArticleDOI
Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens.
Nathalie Landry,Stéphane Pillet,David Favre,Jean-François Poulin,Sonia Trépanier,Bader Yassine-Diab,Brian J. Ward +6 more
TL;DR: Results show that plant-made HA VLP vaccines elicit both strong antibody responses and poly-functional, cross-reactive memory T cells that persist for at least 6 months after vaccination.